Do pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease cardiovascular events^ and if so^ are they cost- effective?
For patients with cardiovascular disease (CVD) already on maximally tolerated statins^ adding evolocumab or alirocumab decreases new CVD events for an additional one in 65 patients compared to placebo over ~2.5 years. Routine use of these agents is not cost-effective at current prices.
Publication Date: 2018-7-3
Last Updated on PCR: 2018-07-03 14:01:45